Insulet Co. (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Insulet Co. (NASDAQ:PODD) have been given an average rating of “Moderate Buy” by the seventeen brokerages that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $292.06.

A number of research analysts have issued reports on the stock. Royal Bank of Canada initiated coverage on shares of Insulet in a report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 target price for the company. Citigroup raised their price objective on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Piper Sandler boosted their target price on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Raymond James restated an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th.

Insulet Trading Down 5.9 %

NASDAQ:PODD opened at $237.06 on Tuesday. The firm has a market cap of $16.65 billion, a P/E ratio of 40.94, a PEG ratio of 3.62 and a beta of 1.29. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet has a 12-month low of $160.19 and a 12-month high of $289.46. The stock’s 50 day simple moving average is $273.56 and its 200-day simple moving average is $253.69.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Equities analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.47% of the stock is currently owned by insiders.

Institutional Trading of Insulet

A number of institutional investors have recently added to or reduced their stakes in PODD. Siemens Fonds Invest GmbH purchased a new stake in shares of Insulet in the fourth quarter worth about $201,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Insulet during the 4th quarter worth approximately $29,993,000. Azzad Asset Management Inc. ADV boosted its holdings in Insulet by 13.2% in the 4th quarter. Azzad Asset Management Inc. ADV now owns 10,161 shares of the medical instruments supplier’s stock worth $2,653,000 after acquiring an additional 1,181 shares during the period. ABLE Financial Group LLC raised its stake in shares of Insulet by 13.6% during the fourth quarter. ABLE Financial Group LLC now owns 4,647 shares of the medical instruments supplier’s stock valued at $1,213,000 after purchasing an additional 557 shares during the period. Finally, Integrated Advisors Network LLC lifted its position in shares of Insulet by 13.1% during the fourth quarter. Integrated Advisors Network LLC now owns 65,769 shares of the medical instruments supplier’s stock worth $17,170,000 after purchasing an additional 7,616 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.